Faculty Opinions recommendation of Human bone marrow activates the Akt pathway in metastatic prostate cells through transactivation of the alpha-platelet-derived growth factor receptor.

Author(s):  
Paola Chiarugi
1987 ◽  
Author(s):  
M C Bryckaert ◽  
A Wasteson ◽  
M Lindroth ◽  
G C Tobelem

A role for the Platelet Derived Growth Factor (PDGF) has been suggested in the abnormal proliferation of bone marrow fibroblasts occuring during myelofibrosis. To investigate this hypothesis, human bone marrow fibroblasts were isolated, and the cultures were characterized by immunofluorescent staining and electron microscopy. Electron microscopy eliminated the presence of endothelial cells by the absence of Weibel-Palade-Bodies. A positive intra and extra cellular antifibro-nectin staining was observed by immunofluorescent staining. The cultured cells didn’t show any labeling with specific antibodies for factor VIII von Willebrand factor, desmin or macrophage. Following the characterization of the bone marrow fibroblasts, using human pure 125I-PDGF, a specific binding of 125I-PDGF was demonstrated. The binding reached a plateau after 3 hours at 20°C, and after 4 hours at 4°C. Addition of unlabeled PDGF decreased this binding until 25 %.Saturation curve and scatchard analysis indicated two classes of sites with respectively 21,000 sites/aall and 37.000 sites/cell with an apparent Kd of 0.3 X 10-10 M and 0.5 X 10-9 M. Normal human serum at a concentration of 20 % induced a maximal DNA synthesis measured by-3H thymidine incorporation. When PDGF was added alone to the cultured fibroblasts at a concentration of 15 ng/ml, it induced a maximal DNA synthesis of 400 %.In the presence of 5 % of Platelet Poor Plasma (PPP), the same concentration of PDGF (15ng/ml) increased the incorporation of 3H thymidine up to 900%.In conclusion i) PDGF binds to human bone marrow fibroblasts, ii) PDGF stimulates their proliferation. These results are in favour of a role of PDGF in the proliferation of bone marrow fibroblasts associated with the development of myelofibrosis.


2018 ◽  
Vol 2018 ◽  
pp. 1-10 ◽  
Author(s):  
Winston Y. Cheung ◽  
Owen Hovey ◽  
Jonathan M. Gobin ◽  
Gauri Muradia ◽  
Jelica Mehic ◽  
...  

Background. Human mesenchymal stromal/stem cells (hMSCs) hold great therapeutic potential due to their immunomodulatory and tissue regenerative properties. Enhancement of biological features of hMSCs by transfection has become a focus of investigation for cell- and gene-based therapies. However, many of the current transient transfection methods result in either low transfection efficiency or high cytotoxicity. Methods. In order to find a transfection method that would address the current issues of low transfection efficiency and high cytotoxicity, 6 commercially available cationic lipid and polymer reagents were tested on human bone marrow-derived MSCs (hBM-MSCs) using GFP as a reporter gene. One transfection method using TransIT-2020 was selected and tested with an emphasis on cell quality (viability, identity, and yield), as well as efficacy with a human placental growth factor (PlGF) plasmid. Results. TransIT-2020 yielded the highest fluorescence signal per cell out of the methods that did not decrease cell recovery. Transfecting GFP to 5 hBM-MSC donors using TransIT-2020 yielded 24–36% GFP-expressing cells with a viability of 85–96%. hBM-MSC identity was unaffected as CD90, CD105, and CD73 markers were retained (>95%+) after transfection. When this method was applied to PlGF expression, there was up to a 220-fold increase in secretion. Both growth and secretion of PlGF in overexpressing hBM-MSC were sustained over 7 days, confirming the sustainability and applicability of the TransIT-2020 transfection system. Discussion. We report a simple and efficient method for transient transfection that has not been reported for hBM-MSCs, encompassing high levels of plasmid expression without significant changes to fundamental hBM-MSC characteristics.


Sign in / Sign up

Export Citation Format

Share Document